Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2012

Filing Date
Filed February 8, 2013
Period End
December 31, 2012
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 8, 2013. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (NBIX) reported total revenues of $53.1 milliona for 2012, down from $77.4 million in 2011, and net income of $5.0 million, or $0.08 per diluted share, compared with $37.6 million in 2011.

The decline reflects the absence of $30.0 millionb in 2011 AbbVie milestone revenue and lower collaboration revenue as the AbbVie and Boehringer Ingelheim collaborative periods were completed in 2012. Management expects revenue to decrease significantly in 2013, does not expect milestone revenue in 2013, and expects a net loss in 2013 as VMAT2 development spending rises. The company's lead clinical program is elagolix, an oral GnRH antagonist for endometriosis and uterine fibroids, which is partnered with AbbVie.

AbbVie made a $75 millionc upfront payment and is responsible for development and commercialization costs; the endometriosis Phase III program began in the second quarter of 2012 with an NDA filing expected in 2016. The company's own pipeline centers on NBI-98854, a VMAT2 inhibitor for tardive dyskinesia, with Kinect (topline expected Q2 2013) and Kinect 2 (topline expected mid-2013) Phase IIb studies underway. Cash, cash equivalents and investments were $173.5 million at year-end 2012, the company had an accumulated deficit of $719.7 million, and it had no outstanding debt.

The company reported no material legal proceedings and said its existing resources, together with investment income and future strategic alliance payments, would fund planned operations for at least the next 12 months. Investors should note that the company has not yet obtained approval for any product, has not generated product sales, and has stated it does not expect to remain profitable or cash flow positive for the foreseeable future.

Key Highlights

  1. Total revenues of $53.1 million in 2012, down from $77.4 million in 2011, driven mainly by $30.0 million of 2011 AbbVie milestones that did not recur.
  2. Net income of $5.0 million ($0.08 per diluted share) in 2012, versus $37.6 million ($0.67 per diluted share) in 2011.
  3. Management expects revenue to decrease significantly in 2013 and a net loss in 2013, with no milestone revenue anticipated.
  4. Lead program elagolix (endometriosis and uterine fibroids) is partnered with AbbVie, which made a $75 million upfront payment and has agreed to up to $480 million in development and regulatory payments and up to $50 million in commercial payments; NDA filing for endometriosis is expected in 2016.
  5. VMAT2 inhibitor NBI-98854 for tardive dyskinesia is in Phase IIb, with Kinect topline data expected in Q2 2013 and Kinect 2 topline data expected in mid-2013.
  6. Cash, cash equivalents and investments totaled $173.5 million at December 31, 2012, with no outstanding debt, and an accumulated deficit of $719.7 million.
  7. January 2012 public offering of 10.9 million shares at $8.10 per share generated net proceeds of approximately $83.0 million.

Financial Statements

FY2012 against FY2011

Line itemFY2012FY2011Change
Revenue$53.14M$77.41M−31.4%
R&D Expenses$37.16M$30.95M+20.1%
Operating Expenses$51.69M$43.49M+18.9%
Operating Income$1.45M$33.92M−95.7%
Net Income$5.03M$37.57M−86.6%
EPS (Basic)$0.08$0.68−88.2%
EPS (Diluted)$0.08$0.67−88.1%
Shares Outstanding (Basic)65.62M55.18M+18.9%
Shares Outstanding (Diluted)66.95M56.35M+18.8%

Frequently Asked Questions

  1. Why did revenue decline sharply in 2012?

    Revenue fell from $77.4 million in 2011 to $53.1 million in 2012, primarily because two AbbVie milestones totaling $30.0 million were recognized in 2011, and sponsored research revenue declined as the AbbVie and Boehringer Ingelheim collaborative development and research periods were completed in 2012.

  2. Is Neurocrine currently selling any products?

    No. The filing states the company has not yet obtained regulatory approval for any product and has not generated revenues from the sale of products. Its revenue comes from collaboration agreements.

  3. What are the company's main near-term catalysts?

    The filing points to Kinect topline data for NBI-98854 in tardive dyskinesia expected in Q2 2013, Kinect 2 topline results expected in mid-2013, and an end of Phase II discussion with the FDA in late 2013. The AbbVie elagolix endometriosis Phase III program is ongoing, with an NDA filing expected in 2016.

  4. Does Neurocrine have enough cash to fund operations?

    The company believes its existing capital resources, together with investment income and future payments due under its strategic alliances, will be sufficient to fund its current and projected requirements for at least the next 12 months. It also notes it may need additional funding and may pursue equity offerings, and it had approximately $150 million of shelf capacity available from a December 2012 registration plus about $37 million remaining under a December 2010 shelf.

  5. What is the status of indiplon?

    Indiplon 5mg and 10mg capsules received an approvable letter from the FDA in December 2007. After that, the company ceased US clinical development and pre-commercialization activities and continues to evaluate alternatives for the program, which is subject to significant uncertainty. Dainippon Sumitomo Pharma holds a license for indiplon in Japan.